Cancer cells often overexpress CD47 to protect themselves from immune-mediated destruction. This overexpression allows them to escape phagocytosis by macrophages, facilitating tumor growth and metastasis. As a result, CD47 is considered a promising target for cancer immunotherapy. Blocking the interaction between CD47 and SIRPĪ± can potentially enhance the immune system's ability to recognize and eliminate cancer cells.
